According to the latest reports, there are nearly 200 hospitals in China providing CAR T-cell therapy for the treatment of lymphoma.
Chimeric antigen receptor (CAR) T-cell therapy is a breakthrough immunotherapy approved in China for the treatment of lymphoma, and application of approval in treating for relapsed or refractory multiple myeloma is currently under China’s National Medical Products Administration’s review.
There are two commercial CAR T-cell therapy products available in China at the moment:
Yescarta (axicabtagene ciloleucel), the first commercial CAR T-cell therapy in China was approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, including:
- diffuse large B-cell lymphoma (DLBCL),
- primary diastinal B-cell lymphoma (PMBCL),
- LBCL transformed from high-grade B-cell lymphoma
- and follicular lymphoma
Carteyva (relmacabtagene autoleucel, relma-cel), the second commercial CAR T-cell therapy in China, developed based on Junos’ JCAR017, was approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (DLBCL) after second-line or more systemic therapy, including:
- diffuse large B-cell lymphoma unspecified,
- follicular lymphoma-transformed diffuse large B Cell lymphoma,
- grade 3b follicular lymphoma, primary mediastinal large B-cell lymphoma,
- allo-B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements (double-hit/triple-hit lymphoma).